CORBEL Catalogue of Services
Why do we need a Catalogue of Services?
Currently there are 13 biological and medical sciences Research Infrastructures (RIs) in Europe, all of them working jointly together in CORBEL towards offering shared services for life-science.
All RIs offer services, i.e. researchers from academia and industry can access their facilities, technologies and expertise. Services can simply be consultation, access to experts, but also access to data and biological samples, use of data analysis tools, access to facilities (e.g. highly specialised microscopes) plus support from technicians and much more.
The CORBEL Catalogue of Services is the first tool to list the main services of all these RIs at a glance and it aims to facilitate the utilisation of RI services by researchers from all over the world.
The Catalogue of Services as displayed below aims to provide you a basic overview on existing services within distinct thematic fields.
You can either use the Catalogue of Services to identify a single RI to help you with your work or you can create your own CORBEL service pipelines, i.e. using several RIs subsequently.
Examples of service pipelines are provided here.
>> In order to improve the catalogue, we kindly ask you to fill in a short feedback form.
What’s your need?
Data & Databases
Technologies & Facilities
- accreditated/certified facilities (ISO certified, GLP, GMP, GCP)
- adaptation / development of assays (compounds etc.)
- adaptation / development of assays (human/non-human samples)
- high-throughput screening
- imaging (biological)
- imaging (medical)
- isolation / cultivation / characterisation of microorganisms
- -omics technology platforms
- plant phenotyping technologies/facilities
- production of high quality protein samples
- structural biology technologies/software
Models & Tools
Expertise & Support
- biomarker validation
- biosecurity / biosafety (incl. regulatory) issues
- data management expertise
- development of project towards a medical application
- ethical / legal issues, informed consent
- innovation management support
- mouse model generation, phenotyping and cryopreservation
- multinational clinical trial (establishment / management / monitoring)
- outbreak / emergency response / epidemiology
- support to submit a project proposal
- systems biology expertise
- training courses
- The following RIs offer complementary services:
Contact person(s): Anne-Charlotte Fauvel
EATRIS is the European infrastructure for translational medicine. The infrastructure brings together resources and services for research communities to translate scientific discoveries into benefits for patients.
Services offered by EATRIS include
- support funding applications (Identification of partners for consortium building, assessment of the project plan's impact and innovation potential)
- translational research facilities and expertise for development of novel biomarkers, diagnostics and therapeutics
- molecular, functional & hybrid imaging technologies, preclinical models, samples, patient cohorts, GMP manufacturing
- regulatory and Health Technology Assessment (HTA) expertise
- advice on intellectual property issues and industry partnering strategy (innovation management)
Costs are calculated on a case by case basis depending on the service required; some services can also be provided as part of funding proposals with EATRIS joining consortia as partner or subcontractor.
For further information please contact us.
Services performed can be offered either centrally by the coordination and support team based in Amsterdam or remotely by the EATRIS institutions.
Why work with us
Translating novel biology insights into effective interventions or medical applications is a highly complex process. It requires significant dedicated expertise, facilities and resources. We believe in your medical innovation and we want to support you by bringing together the multi-disciplinary expertise and infrastructure required for optimising your translational trajectory. Working with EATRIS gives greater confidence in the translational feasibility of your project and its impact.
FR, NL, CZ, HR, SE, NO, FI, IT, ES, SI, LU, LV, PO, BG
Contact person(s): Diana Stepanyan-Yerdamian, Dylan Bonfils, contact(at)erinha.eu
ERINHA is a pan-European distributed life sciences research Infrastructure dedicated to the study of highly infectious emerging and re-emerging high-consequence pathogens (RG4 & unknown). It brings together leading European high containment and complementary research facilities and expertise required to perform cutting-edge research on highly infectious diseases. ERINHA provides access to its state of art BSL-4 laboratories and complementary capacities and expertise to perform excellence orientated in-vitro and in-vivo research projects, trainings and advise. A wide range of capabilities and functions from high basic research laboratory capacities to NHP modeling research are provided by ERINHA, as well as expertise of senior scientists and access to complementary functions (from BSL1 to BSL4, genomics, proteomics etc.).
ERINHA produces the ideal environment to facilitate coordination of research on high-consequence pathogens in Europe. The infrastructure will contribute to the enhancement of the European and global capacity, capability and emergency preparedness in the response to global outbreaks.
Since 2018, ERINHA has been granted landmark status by the European Strategy Forum on Research Infrastructures (ESFRI).
The services offered by ERINHA include
- Access to state of art European high containment (BSL4 & BSL3) and complementary facilities to advance research on high-consequence pathogens. In-vivo testing with a variety of animal models (including small rodents, ferrets, and non-human primates). In-vitro experiments using highly pathogenic agents with both in-person and remote access possibilities.
- Project coordination and management of large scale research programmes on high consequence pathogens
- Training (General Biosecurity Training; Operations of a Biosafety Laboratory; Training for potential users)
- Advice and scientific expertise provider: RG4 pathogens research, containment facilities construction, biosafety/biosecurity issues, sample transport etc.
- Access to pathogens specimens
For access costs information contact ERINHA Central Coordinating Unit (CCU) at contact(at)erinha.eu
ERINHA provides in-person and remote access to its services. Projects can be submitted by academic, public and industrial users. For more information contact ERINHA CCU at contact(at)erinha.eu
Why work with us
The 2014-2015 Ebola outbreak and cases in Europe demonstrated the worldwide vulnerability and need for common action putting together rare high containment capacities and expertise to be able to increase European and global preparedness for outbreaks of high consequence pathogens. ERINHA facilitates access to required infrastructure capacities thanks to its CCU and multiple high containment and complementary European resources. It is a unique coordinated infrastrucuture providing transnational access to its facilities, large scope of services and shorter delays in access.
Austria (Medical University of Graz), Belgium (KUL), France (Inserm), Hungary (Ministry of Human Capacities), Netherlands (ERASMUS MC), Portugal (INSA), Spain (Instituto de Salud Carlos III), Sweden (FOHM)
Contact person(s): Project Manager: Dr. Tanja Miletic
EU-OPENSCREEN integrates high-capacity screening platforms throughout Europe, which jointly use a rationally selected compound collection, comprising up to 140.000 commercial and proprietary compounds collected from European chemists. EU-OPENSCREEN offers to researchers from academic institutions, SMEs and industrial organisations open access to its shared resources.
EU-OPENSCREEN will collaboratively develop novel molecular tool compounds with external users from various disciplines of the life sciences.
Services provided by EU-OPENSCREEN include
- high-throughput compound/ drug screening (HTS): HTS of an assay against the EU-OPENSCREEN chemical collection (> 100,000 compounds); in silico profiling; hit selection; confirmatory screening; basic counter screening; basic SAR based on screening data; QC of confirmed hits
- access to a unique European compound collection: EU-OPENSCREEN chemical collection (> 100,000 compounds)
- assay adaption: This assay adaptation process will involve a strong emphasis on quality, including: quality control of reagents; (patho-)physiological relevance; pharmacological consistency; robustness; minimised variability; and tracking of statistical descriptors (e.g. signal to background and the Z’ factor)
- chemical optimization and profiling of preliminary ‘hits’
- bioprofiling of donated compounds: All compounds donated by the user which enter the EU-OPENSCREEN ERIC compound collection are characterised and annotated for basic physico-chemical (e.g. identity, solubility, light absorbance and fluorescence) and essential to know biological properties (cytotoxicity, antibiotic, antifungal etc.) by testing in a standard panel of assays.
- provision of standardised data: All data generated through QC/bioprofiling and screening activities will be published in EU-OPENSCREEN’s open-access database with an optional ‘grace’ period (i.e. delayed publication of data). Large-scale open-access data provide the basis for computational data integration to obtain a systematic view, allow for prediction of drug-target interactions and networks as well as of adverse effects and drug combinations. The access to the EU-OPENSCREEN database will utilize the facilities of ChEMBL.
- training and education activities
A screening project at a typical EU-OPENSCREEN screening site will cost 50-250k €, strongly depending on the number of screened substances and the maturity/ complexity of the assay.
A compound replenishment fee structure applies to all projects using the EU-OPENSCREEN compound collection and users from countries which are members of the EU-OPENSCREEN ERIC will receive a discount on this cost.
For further information please contact us.
Users are requested to submit project proposal to the EU-OPENSCREEN office. Depending on the project requirements, the RI can be assessed remotely or on-site.
Why work with us
The majority of scientists in Europe do not have access to suitable technology platforms and compound collections, which are generally expensive to purchase, operate and maintain. As a large-scale research infrastructure (RI) with an ‘open’ pre-competitive character, EU-OPENSCREEN will cost-effectively overcome this limitation by: involving and providing access to Europe’s leading screening platforms and chemistry groups; offering a jointly used rationally designed compound collection; and operating an open-access bioactivity database which will be accessible on a global basis. EU-OPENSCREEN offers to support you through grant application processes and beyond for funding involving screening projects.
CZ, FI, DE, LV, NO, PO, ES, DK
Please note: Most of the RIs are constantly developing their portfolio of services, so if you do not find the service/tool you are looking for, do not hesitate to contact the RI and ask for it!